Atlanta GA 下咽癌临床试验
6项针对 下咽癌的研究正在 Atlanta及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
招募中2 期
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
招募中1/2 期
- Winship Cancer Institute - Emory University, Atlanta
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
招募中
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
招募中1 期
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
招募中2 期
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
招募中早期 I 期
- Emory University Hospital Midtown, Atlanta
其他城市的 下咽癌试验
- Chicago, IL6 项研究
- Richmond, VA5 项研究
- Kansas City, MO5 项研究
- Milwaukee, WI5 项研究
- Bloomington, IL5 项研究
- Stevens Point, WI5 项研究
- Wausau, WI5 项研究
- Cape Girardeau, MO5 项研究
- Peoria, IL5 项研究
- Joliet, IL5 项研究
- Cincinnati, OH4 项研究
- Kansas City, KS4 项研究
Atlanta的其他研究
- 癌症(所有类型)49 项研究
- 非小细胞肺癌47 项研究
- 多发性骨髓瘤42 项研究
- 乳腺癌41 项研究
- 前列腺癌33 项研究
- 急性髓系白血病31 项研究
- 卵巢癌29 项研究
- 结直肠癌29 项研究
- 肺癌29 项研究
- 转移性癌症28 项研究
- 重度抑郁症25 项研究
- 心力衰竭25 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。